Harbin Medisan Pharma: Stagnant Losses Amid China’s Surge in Innovation Drugs
Harbin Medisan Pharmaceutical faces loss‑making, low‑margin operations amid China’s booming drug innovation—investors eye high risk and a need for strategic pivot.
5 minutes to read